Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3185427 | 0.88 | MLKL (0.53) | USP2L3MBTL1HTTLMNAALDH1A1 | |
| SCHEMBL555591 | 0.82 | HTT (0.52) | USP2HTTLMNAALDH1A1NPSR1 | |
| SCHEMBL27583007 | 0.80 | LMNA (0.49) | USP2L3MBTL1HTTLMNAALDH1A1 | |
| SCHEMBL835889 | 0.80 | ALDH1A1 (0.43) | USP2HTTLMNAALDH1A1POLB | |
| SCHEMBL5718940 | 0.78 | USP2 (0.72) | USP2L3MBTL1HTTLMNAALDH1A1 | |
| SCHEMBL17993315 | 0.76 | CYP1A2 (0.67) | USP2L3MBTL1HTTLMNAALDH1A1 | |
| SCHEMBL554580 | 0.76 | KMT2A (0.48) | L3MBTL1HTTLMNACYP1A2CYP2C19 | |
| SCHEMBL3188422 | 0.75 | CYP1A2 (0.62) | USP2L3MBTL1HTTLMNAALDH1A1 | |
| SCHEMBL28553445 | 0.73 | NCOA1 (0.38) | L3MBTL1ALDH1A1POLBCYP1A2CYP2C19 | |
| SCHEMBL556093 | 0.73 | MAPT (0.57) | HTTLMNAALDH1A1POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20130150383-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150383-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-13 | — | — | US | disclosed |
| EP-1781657-B1 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-8394808-B2 | HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes | GLAXOSMITHKLINE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394808-B2 | HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes | GLAXOSMITHKLINE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8268839-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268839-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100160354-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-06-24 | — | — | US | disclosed |
| US-20100160354-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-06-24 | — | — | US | disclosed |
| US-7713982-B2 | Xanthines with HM74A receptor activity | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713982-B2 | Xanthines with HM74A receptor activity | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | disclosed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| EP-1781657-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2005077950-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135456-A1 | Medicaments with hm74a receptor activity | HCAR1, GPR84, HCAR3 | USP2 3953/4885L3MBTL1 4195/4885HTT 2048/4885 |
| US-20150080418-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | USP2 4163/4885L3MBTL1 4441/4885HTT 1778/4885 |
| US-20130150383-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | USP2 4163/4885L3MBTL1 4441/4885HTT 1778/4885 |
| US-20100160354-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | USP2 4163/4885L3MBTL1 4441/4885HTT 1778/4885 |
| US-20100010021-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | USP2 4163/4885L3MBTL1 4441/4885HTT 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.